Research programme: obesity therapies - Biocon

Drug Profile

Research programme: obesity therapies - Biocon

Alternative Names: NLC-002

Latest Information Update: 10 Apr 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biocon
  • Class
  • Mechanism of Action Cholecystokinin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Obesity

Most Recent Events

  • 27 Feb 2004 NLC 002 is available for partnering for obesity worldwide (2nd Annual BioPartnering North America Conference (BPN-2004) (http://www.nobexcorp.com)
  • 24 Sep 2002 Lead compound of the programme has been identified as NLC 002
  • 19 Mar 2002 Preclinical trials in Obesity in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top